Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PPID | Q08752 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | MC3R | P41968 | 2/20 | 0.52 |
| ▸ | MC1R | Q01726 | 2/20 | 0.52 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038120 | 1.00 | EPHX2 (0.59) | EPHX2RIPK1ALDH1A1POLBPPID | |
| SCHEMBL28303699 | 1.00 | EPHX2 (0.59) | EPHX2RIPK1ALDH1A1POLBPPID | |
| SCHEMBL28005101 | 0.95 | ALDH1A1 (0.56) | EPHX2RIPK1ALDH1A1POLBPPID | |
| SCHEMBL25884649 | 0.85 | EPHX2 (0.63) | EPHX2RIPK1POLBPPIDHSP90AA1 | |
| SCHEMBL12964250 | 0.83 | RIPK1 (0.64) | EPHX2RIPK1PPIDHSP90AA1HSP90AB1 | |
| SCHEMBL1779437 | 0.83 | HDAC1 (0.53) | EPHX2PPID | |
| SCHEMBL8004499 | 0.83 | HDAC1 (0.53) | EPHX2PPID | |
| Hydrochloric Acid SCHEMBL27412469 | 0.82 | RIPK1 (0.62) | EPHX2RIPK1PPIDHSP90AA1HSP90AB1 | |
| SCHEMBL1780619 | 0.81 | GPR183 (0.47) | EPHX2RIPK1PPIDAADAT | |
| SCHEMBL24264808 | 0.81 | RIPK1 (0.61) | EPHX2RIPK1PPIDHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2017-10-05 | — | — | US | disclosed |
| US-9770435-B2 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | OGEDA SA (BE) | 2017-09-26 | — | — | US | disclosed |
| US-9695120-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2017-07-04 | — | — | US | disclosed |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3074008-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | Euroscreen S.A. (BE) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078949-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN SA (BE) | 2015-06-04 | — | — | WO | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| EP-2513053-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | Euroscreen S.A. (BE) | 2012-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | EPHX2 3066/4885RIPK1 3087/4885ALDH1A1 1244/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | EPHX2 3066/4885RIPK1 3087/4885ALDH1A1 1244/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | EPHX2 3066/4885RIPK1 3087/4885ALDH1A1 1244/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | EPHX2 3128/4885RIPK1 1961/4885ALDH1A1 1118/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | EPHX2 3550/4885RIPK1 2863/4885ALDH1A1 1453/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | EPHX2 3066/4885RIPK1 3087/4885ALDH1A1 1244/4885 |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, FFAR3 | EPHX2 3447/4885RIPK1 3094/4885ALDH1A1 1764/4885 |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | EPHX2 3128/4885RIPK1 1961/4885ALDH1A1 1118/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | EPHX2 1730/4885RIPK1 3670/4885ALDH1A1 1518/4885 |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | PTGS1, PTGES, PTGER1 | EPHX2 317/4885RIPK1 4058/4885ALDH1A1 393/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | EPHX2 3095/4885RIPK1 3126/4885ALDH1A1 1279/4885 |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | EPHX2 3066/4885RIPK1 3087/4885ALDH1A1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.